Share Price and Basic Stock Data
Last Updated: January 1, 2026, 3:43 pm
| PEG Ratio | 0.78 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Gennex Laboratories Ltd operates in the pharmaceutical sector, with a current market capitalization of ₹347 Cr and a share price of ₹14.3. The company reported sales of ₹66 Cr for FY 2023, which rose to ₹87 Cr for FY 2024, indicating a growth trajectory. The trailing twelve months (TTM) revenue reached ₹152 Cr, reflecting a consistent increase in operational performance. Quarterly sales figures also demonstrate this upward trend, with sales for June 2025 recorded at ₹34.18 Cr and projected to rise to ₹37.24 Cr by September 2025. Gennex’s operating profit margin (OPM) stood at 14.77%, suggesting effective cost management. However, the company faces challenges in maintaining consistent quarterly performance, as evidenced by fluctuations in sales and operating profit across various quarters. The cash conversion cycle (CCC) of 123 days indicates a relatively high duration for converting investments into cash flow, which could impact liquidity. Overall, Gennex Laboratories is positioned for growth, but must address certain operational inefficiencies to maximize revenue potential.
Profitability and Efficiency Metrics
The profitability of Gennex Laboratories is reflected in its net profit of ₹19 Cr for FY 2025, translating to an earnings per share (EPS) of ₹0.80. The company’s return on equity (ROE) stood at 10.2%, while the return on capital employed (ROCE) was reported at 13.0%. These figures indicate a stable return generation capability, although they are somewhat below the industry average, suggesting room for improvement. Operating profit margins have shown variability, with a high of 30.87% in June 2023, followed by a decrease to 14.77% by September 2025. The interest coverage ratio (ICR) of 7.52x indicates a strong ability to meet interest obligations, which is a positive sign for financial stability. However, the company’s fluctuating OPM and net profit margins, which stood at 13.14% for FY 2025, reveal potential inefficiencies in managing operational costs and pricing strategies. Addressing these issues could enhance profitability and shareholder value.
Balance Sheet Strength and Financial Ratios
Gennex Laboratories reported total assets of ₹256 Cr for FY 2025, with total liabilities of ₹256 Cr as well, indicating a balanced financial structure. The company’s equity capital remained stable at ₹23 Cr, while reserves increased significantly to ₹164 Cr, reflecting a strong retention of earnings. Borrowings stood at ₹10 Cr, which is low relative to the company’s equity, resulting in a debt-to-equity ratio of 0.05, highlighting minimal reliance on external debt. The current ratio of 4.07x indicates robust liquidity, while the quick ratio of 3.26x further reinforces this strength. However, the cash conversion cycle of 123 days poses a concern regarding the efficiency of asset utilization. The book value per share rose to ₹8.21, demonstrating an increase in shareholder value. Overall, Gennex Laboratories displays solid financial health with low leverage, but must enhance operational efficiency to optimize asset utilization.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Gennex Laboratories reveals a significant public ownership of 76.38%, while promoter holding stood at 23.62%. This distribution indicates a healthy level of public confidence in the company, as evidenced by the increase in the number of shareholders from 58,248 in December 2022 to 90,320 by September 2025. The stability of promoter holdings, which have remained relatively constant over recent quarters, reflects a commitment to the company’s long-term strategy. However, the decline in promoter holding from 23.61% to 18.41% between December 2023 and March 2024 may raise concerns about insider confidence among investors. The absence of foreign institutional investors (FIIs) and domestic institutional investors (DIIs) suggests potential opportunities for Gennex to attract institutional capital. Overall, while the public’s stake in Gennex Laboratories is robust, the company must work to enhance institutional interest to bolster investor confidence further.
Outlook, Risks, and Final Insight
Gennex Laboratories is positioned for growth, supported by increasing revenue and a solid financial foundation. However, the company faces risks such as fluctuating operational performance, as evidenced by its inconsistent quarterly sales and profit margins. Additionally, the extended cash conversion cycle may hinder liquidity and operational flexibility. To mitigate these risks, Gennex should focus on enhancing operational efficiency and improving supply chain management. Strengths such as low debt levels and a high interest coverage ratio provide a buffer against economic fluctuations. The company’s ability to attract institutional investors could further enhance its market presence and financial stability. Overall, while Gennex Laboratories has promising growth potential, addressing operational challenges and fostering investor confidence will be critical to achieving its long-term objectives.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 131 Cr. | 104 | 217/84.3 | 29.0 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.54 Cr. | 1.85 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,800 Cr. | 441 | 479/192 | 99.4 | 24.3 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 35.8 Cr. | 48.2 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 52.7 Cr. | 36.0 | 36.6/17.0 | 125 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,151.58 Cr | 1,147.42 | 53.40 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 19.62 | 14.63 | 20.80 | 16.52 | 18.18 | 21.39 | 35.52 | 28.32 | 33.38 | 40.01 | 40.33 | 34.18 | 37.24 |
| Expenses | 17.76 | 12.81 | 17.28 | 11.42 | 12.41 | 16.59 | 29.26 | 24.10 | 25.92 | 32.86 | 38.31 | 29.11 | 31.74 |
| Operating Profit | 1.86 | 1.82 | 3.52 | 5.10 | 5.77 | 4.80 | 6.26 | 4.22 | 7.46 | 7.15 | 2.02 | 5.07 | 5.50 |
| OPM % | 9.48% | 12.44% | 16.92% | 30.87% | 31.74% | 22.44% | 17.62% | 14.90% | 22.35% | 17.87% | 5.01% | 14.83% | 14.77% |
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.47 | 0.00 | 0.00 | 3.68 | 2.28 | 2.06 |
| Interest | 0.10 | 0.19 | 0.63 | 0.73 | 0.78 | 0.83 | 0.73 | 0.73 | 0.22 | 0.84 | 1.20 | 0.98 | 1.03 |
| Depreciation | 0.36 | 0.18 | 0.37 | 0.65 | 1.03 | 0.45 | 0.23 | 0.45 | 1.11 | 0.50 | 0.54 | 0.50 | 0.47 |
| Profit before tax | 1.40 | 1.45 | 2.52 | 3.72 | 3.96 | 3.52 | 5.30 | 5.51 | 6.13 | 5.81 | 3.96 | 5.87 | 6.06 |
| Tax % | 25.00% | 24.83% | 19.05% | 23.39% | 22.47% | 21.31% | 15.28% | 15.43% | 12.23% | 12.91% | 22.22% | 14.48% | 9.08% |
| Net Profit | 1.05 | 1.08 | 2.04 | 2.85 | 3.07 | 2.76 | 4.50 | 4.66 | 5.38 | 5.06 | 3.07 | 5.01 | 5.51 |
| EPS in Rs | 0.06 | 0.07 | 0.12 | 0.16 | 0.17 | 0.15 | 0.20 | 0.19 | 0.21 | 0.20 | 0.10 | 0.20 | 0.21 |
Last Updated: December 26, 2025, 7:46 pm
Below is a detailed analysis of the quarterly data for Gennex Laboratories Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 37.24 Cr.. The value appears strong and on an upward trend. It has increased from 34.18 Cr. (Jun 2025) to 37.24 Cr., marking an increase of 3.06 Cr..
- For Expenses, as of Sep 2025, the value is 31.74 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 29.11 Cr. (Jun 2025) to 31.74 Cr., marking an increase of 2.63 Cr..
- For Operating Profit, as of Sep 2025, the value is 5.50 Cr.. The value appears strong and on an upward trend. It has increased from 5.07 Cr. (Jun 2025) to 5.50 Cr., marking an increase of 0.43 Cr..
- For OPM %, as of Sep 2025, the value is 14.77%. The value appears to be declining and may need further review. It has decreased from 14.83% (Jun 2025) to 14.77%, marking a decrease of 0.06%.
- For Other Income, as of Sep 2025, the value is 2.06 Cr.. The value appears to be declining and may need further review. It has decreased from 2.28 Cr. (Jun 2025) to 2.06 Cr., marking a decrease of 0.22 Cr..
- For Interest, as of Sep 2025, the value is 1.03 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.98 Cr. (Jun 2025) to 1.03 Cr., marking an increase of 0.05 Cr..
- For Depreciation, as of Sep 2025, the value is 0.47 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.50 Cr. (Jun 2025) to 0.47 Cr., marking a decrease of 0.03 Cr..
- For Profit before tax, as of Sep 2025, the value is 6.06 Cr.. The value appears strong and on an upward trend. It has increased from 5.87 Cr. (Jun 2025) to 6.06 Cr., marking an increase of 0.19 Cr..
- For Tax %, as of Sep 2025, the value is 9.08%. The value appears to be improving (decreasing) as expected. It has decreased from 14.48% (Jun 2025) to 9.08%, marking a decrease of 5.40%.
- For Net Profit, as of Sep 2025, the value is 5.51 Cr.. The value appears strong and on an upward trend. It has increased from 5.01 Cr. (Jun 2025) to 5.51 Cr., marking an increase of 0.50 Cr..
- For EPS in Rs, as of Sep 2025, the value is 0.21. The value appears strong and on an upward trend. It has increased from 0.20 (Jun 2025) to 0.21, marking an increase of 0.01.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:40 am
| Metric | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 42 | 44 | 56 | 56 | 60 | 61 | 66 | 87 | 138 | 152 |
| Expenses | 37 | 42 | 52 | 52 | 53 | 56 | 61 | 70 | 121 | 132 |
| Operating Profit | 5 | 2 | 4 | 3 | 7 | 5 | 5 | 17 | 17 | 20 |
| OPM % | 11% | 5% | 7% | 6% | 11% | 9% | 7% | 20% | 12% | 13% |
| Other Income | 0 | 1 | 1 | 1 | 0 | 1 | 4 | 5 | 10 | 8 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 4 | 4 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 |
| Profit before tax | 3 | 1 | 3 | 3 | 5 | 5 | 6 | 16 | 21 | 22 |
| Tax % | 13% | 42% | 26% | 27% | 20% | 23% | 23% | 20% | 15% | |
| Net Profit | 3 | 1 | 2 | 2 | 4 | 4 | 5 | 13 | 18 | 19 |
| EPS in Rs | 0.14 | 0.04 | 0.12 | 0.10 | 0.21 | 0.21 | 0.28 | 0.58 | 0.80 | 0.71 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -66.67% | 100.00% | 0.00% | 100.00% | 0.00% | 25.00% | 160.00% | 38.46% |
| Change in YoY Net Profit Growth (%) | 0.00% | 166.67% | -100.00% | 100.00% | -100.00% | 25.00% | 135.00% | -121.54% |
Gennex Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 8 years from 2017-2018 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 20% |
| 3 Years: | 31% |
| TTM: | 43% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 56% |
| 3 Years: | 61% |
| TTM: | 13% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 20% |
| 3 Years: | 17% |
| 1 Year: | -38% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 9% |
| 3 Years: | 9% |
| Last Year: | 9% |
Last Updated: September 5, 2025, 3:36 pm
Balance Sheet
Last Updated: December 4, 2025, 2:56 am
| Month | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 13 | 13 | 13 | 13 | 13 | 13 | 18 | 23 | 23 | 24 |
| Reserves | 18 | 19 | 21 | 23 | 27 | 31 | 62 | 148 | 164 | 189 |
| Borrowings | 4 | 2 | 5 | 5 | 7 | 10 | 1 | 6 | 10 | 88 |
| Other Liabilities | 14 | 16 | 13 | 16 | 12 | 14 | 51 | 54 | 59 | 55 |
| Total Liabilities | 49 | 50 | 52 | 57 | 59 | 68 | 132 | 230 | 256 | 357 |
| Fixed Assets | 16 | 16 | 16 | 15 | 14 | 14 | 74 | 56 | 60 | 76 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 5 | 0 |
| Investments | 7 | 7 | 7 | 7 | 7 | 7 | 0 | 0 | 0 | 0 |
| Other Assets | 26 | 28 | 29 | 35 | 38 | 48 | 59 | 172 | 191 | 281 |
| Total Assets | 49 | 50 | 52 | 57 | 59 | 68 | 132 | 230 | 256 | 357 |
Below is a detailed analysis of the balance sheet data for Gennex Laboratories Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 24.00 Cr.. The value appears strong and on an upward trend. It has increased from 23.00 Cr. (Mar 2025) to 24.00 Cr., marking an increase of 1.00 Cr..
- For Reserves, as of Sep 2025, the value is 189.00 Cr.. The value appears strong and on an upward trend. It has increased from 164.00 Cr. (Mar 2025) to 189.00 Cr., marking an increase of 25.00 Cr..
- For Borrowings, as of Sep 2025, the value is 88.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 10.00 Cr. (Mar 2025) to 88.00 Cr., marking an increase of 78.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 55.00 Cr.. The value appears to be improving (decreasing). It has decreased from 59.00 Cr. (Mar 2025) to 55.00 Cr., marking a decrease of 4.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 357.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 256.00 Cr. (Mar 2025) to 357.00 Cr., marking an increase of 101.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 76.00 Cr.. The value appears strong and on an upward trend. It has increased from 60.00 Cr. (Mar 2025) to 76.00 Cr., marking an increase of 16.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 5.00 Cr. (Mar 2025) to 0.00 Cr., marking a decrease of 5.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 281.00 Cr.. The value appears strong and on an upward trend. It has increased from 191.00 Cr. (Mar 2025) to 281.00 Cr., marking an increase of 90.00 Cr..
- For Total Assets, as of Sep 2025, the value is 357.00 Cr.. The value appears strong and on an upward trend. It has increased from 256.00 Cr. (Mar 2025) to 357.00 Cr., marking an increase of 101.00 Cr..
Notably, the Reserves (189.00 Cr.) exceed the Borrowings (88.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 1.00 | 0.00 | -1.00 | -2.00 | 0.00 | -5.00 | 4.00 | 11.00 | 7.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 90 | 87 | 68 | 41 | 55 | 67 | 52 | 75 | 37 |
| Inventory Days | 43 | 31 | 57 | 78 | 50 | 72 | 139 | 184 | 135 |
| Days Payable | 139 | 161 | 88 | 86 | 59 | 72 | 63 | 111 | 49 |
| Cash Conversion Cycle | -7 | -43 | 38 | 34 | 46 | 67 | 129 | 148 | 123 |
| Working Capital Days | 74 | 75 | 56 | 87 | 108 | 87 | 23 | 255 | 214 |
| ROCE % | 6% | 11% | 8% | 14% | 12% | 11% | 14% | 12% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | 0.80 | 0.66 | 0.42 | 0.33 | 0.32 |
| Diluted EPS (Rs.) | 0.78 | 0.66 | 0.42 | 0.33 | 0.32 |
| Cash EPS (Rs.) | 0.88 | 0.68 | 0.32 | 0.37 | 0.38 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 8.21 | 7.49 | 4.46 | 3.46 | 3.14 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 8.21 | 7.49 | 4.46 | 3.46 | 3.14 |
| Revenue From Operations / Share (Rs.) | 6.06 | 3.81 | 3.64 | 4.84 | 4.72 |
| PBDIT / Share (Rs.) | 1.19 | 0.96 | 0.47 | 0.53 | 0.55 |
| PBIT / Share (Rs.) | 1.11 | 0.86 | 0.42 | 0.47 | 0.48 |
| PBT / Share (Rs.) | 0.94 | 0.72 | 0.35 | 0.40 | 0.40 |
| Net Profit / Share (Rs.) | 0.79 | 0.57 | 0.27 | 0.31 | 0.31 |
| NP After MI And SOA / Share (Rs.) | 0.79 | 0.57 | 0.27 | 0.31 | 0.31 |
| PBDIT Margin (%) | 19.68 | 25.29 | 13.17 | 11.04 | 11.83 |
| PBIT Margin (%) | 18.24 | 22.56 | 11.77 | 9.75 | 10.35 |
| PBT Margin (%) | 15.51 | 19.01 | 9.71 | 8.32 | 8.48 |
| Net Profit Margin (%) | 13.14 | 15.19 | 7.50 | 6.40 | 6.76 |
| NP After MI And SOA Margin (%) | 13.14 | 15.19 | 7.50 | 6.40 | 6.76 |
| Return on Networth / Equity (%) | 9.70 | 7.73 | 6.12 | 8.95 | 10.16 |
| Return on Capital Employeed (%) | 11.89 | 10.31 | 7.51 | 13.62 | 15.49 |
| Return On Assets (%) | 7.07 | 5.72 | 3.71 | 5.76 | 6.85 |
| Total Debt / Equity (X) | 0.05 | 0.03 | 0.01 | 0.23 | 0.18 |
| Asset Turnover Ratio (%) | 0.56 | 0.47 | 0.65 | 0.96 | 1.03 |
| Current Ratio (X) | 4.07 | 4.01 | 1.65 | 1.95 | 1.98 |
| Quick Ratio (X) | 3.26 | 3.39 | 1.12 | 1.63 | 1.71 |
| Inventory Turnover Ratio (X) | 4.51 | 2.83 | 4.00 | 6.27 | 5.49 |
| Interest Coverage Ratio (X) | 7.52 | 7.13 | 6.39 | 7.70 | 9.49 |
| Interest Coverage Ratio (Post Tax) (X) | 6.06 | 5.28 | 4.63 | 5.47 | 6.93 |
| Enterprise Value (Cr.) | 236.62 | 310.20 | 93.24 | 97.07 | 55.76 |
| EV / Net Operating Revenue (X) | 1.72 | 3.58 | 1.42 | 1.59 | 0.93 |
| EV / EBITDA (X) | 8.72 | 14.14 | 10.78 | 14.36 | 7.90 |
| MarketCap / Net Operating Revenue (X) | 1.99 | 4.14 | 1.54 | 1.56 | 0.82 |
| Price / BV (X) | 1.47 | 2.11 | 1.26 | 2.17 | 1.25 |
| Price / Net Operating Revenue (X) | 1.99 | 4.14 | 1.54 | 1.56 | 0.82 |
| EarningsYield | 0.06 | 0.03 | 0.04 | 0.04 | 0.08 |
After reviewing the key financial ratios for Gennex Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.80. This value is below the healthy minimum of 5. It has increased from 0.66 (Mar 24) to 0.80, marking an increase of 0.14.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.78. This value is below the healthy minimum of 5. It has increased from 0.66 (Mar 24) to 0.78, marking an increase of 0.12.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.88. This value is below the healthy minimum of 3. It has increased from 0.68 (Mar 24) to 0.88, marking an increase of 0.20.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 8.21. It has increased from 7.49 (Mar 24) to 8.21, marking an increase of 0.72.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 8.21. It has increased from 7.49 (Mar 24) to 8.21, marking an increase of 0.72.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 6.06. It has increased from 3.81 (Mar 24) to 6.06, marking an increase of 2.25.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 1.19. This value is below the healthy minimum of 2. It has increased from 0.96 (Mar 24) to 1.19, marking an increase of 0.23.
- For PBIT / Share (Rs.), as of Mar 25, the value is 1.11. This value is within the healthy range. It has increased from 0.86 (Mar 24) to 1.11, marking an increase of 0.25.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.94. This value is within the healthy range. It has increased from 0.72 (Mar 24) to 0.94, marking an increase of 0.22.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.79. This value is below the healthy minimum of 2. It has increased from 0.57 (Mar 24) to 0.79, marking an increase of 0.22.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 0.79. This value is below the healthy minimum of 2. It has increased from 0.57 (Mar 24) to 0.79, marking an increase of 0.22.
- For PBDIT Margin (%), as of Mar 25, the value is 19.68. This value is within the healthy range. It has decreased from 25.29 (Mar 24) to 19.68, marking a decrease of 5.61.
- For PBIT Margin (%), as of Mar 25, the value is 18.24. This value is within the healthy range. It has decreased from 22.56 (Mar 24) to 18.24, marking a decrease of 4.32.
- For PBT Margin (%), as of Mar 25, the value is 15.51. This value is within the healthy range. It has decreased from 19.01 (Mar 24) to 15.51, marking a decrease of 3.50.
- For Net Profit Margin (%), as of Mar 25, the value is 13.14. This value exceeds the healthy maximum of 10. It has decreased from 15.19 (Mar 24) to 13.14, marking a decrease of 2.05.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 13.14. This value is within the healthy range. It has decreased from 15.19 (Mar 24) to 13.14, marking a decrease of 2.05.
- For Return on Networth / Equity (%), as of Mar 25, the value is 9.70. This value is below the healthy minimum of 15. It has increased from 7.73 (Mar 24) to 9.70, marking an increase of 1.97.
- For Return on Capital Employeed (%), as of Mar 25, the value is 11.89. This value is within the healthy range. It has increased from 10.31 (Mar 24) to 11.89, marking an increase of 1.58.
- For Return On Assets (%), as of Mar 25, the value is 7.07. This value is within the healthy range. It has increased from 5.72 (Mar 24) to 7.07, marking an increase of 1.35.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.05. This value is within the healthy range. It has increased from 0.03 (Mar 24) to 0.05, marking an increase of 0.02.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.56. It has increased from 0.47 (Mar 24) to 0.56, marking an increase of 0.09.
- For Current Ratio (X), as of Mar 25, the value is 4.07. This value exceeds the healthy maximum of 3. It has increased from 4.01 (Mar 24) to 4.07, marking an increase of 0.06.
- For Quick Ratio (X), as of Mar 25, the value is 3.26. This value exceeds the healthy maximum of 2. It has decreased from 3.39 (Mar 24) to 3.26, marking a decrease of 0.13.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.51. This value is within the healthy range. It has increased from 2.83 (Mar 24) to 4.51, marking an increase of 1.68.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 7.52. This value is within the healthy range. It has increased from 7.13 (Mar 24) to 7.52, marking an increase of 0.39.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 6.06. This value is within the healthy range. It has increased from 5.28 (Mar 24) to 6.06, marking an increase of 0.78.
- For Enterprise Value (Cr.), as of Mar 25, the value is 236.62. It has decreased from 310.20 (Mar 24) to 236.62, marking a decrease of 73.58.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.72. This value is within the healthy range. It has decreased from 3.58 (Mar 24) to 1.72, marking a decrease of 1.86.
- For EV / EBITDA (X), as of Mar 25, the value is 8.72. This value is within the healthy range. It has decreased from 14.14 (Mar 24) to 8.72, marking a decrease of 5.42.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.99. This value is within the healthy range. It has decreased from 4.14 (Mar 24) to 1.99, marking a decrease of 2.15.
- For Price / BV (X), as of Mar 25, the value is 1.47. This value is within the healthy range. It has decreased from 2.11 (Mar 24) to 1.47, marking a decrease of 0.64.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.99. This value is within the healthy range. It has decreased from 4.14 (Mar 24) to 1.99, marking a decrease of 2.15.
- For EarningsYield, as of Mar 25, the value is 0.06. This value is below the healthy minimum of 5. It has increased from 0.03 (Mar 24) to 0.06, marking an increase of 0.03.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Gennex Laboratories Ltd:
- Net Profit Margin: 13.14%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 11.89% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 9.7% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 6.06
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 3.26
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 21.5 (Industry average Stock P/E: 53.4)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.05
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 13.14%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Sy. No.133, Sangareddy Dist. Telangana 502325 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Arihant Baid | Managing Director |
| Dr. A R R Pantulu | Non Executive Director |
| Mr. Sandeep Kumar Daga | Non Executive Director |
| Mr. A S Nageswar Rao | Independent Director |
| Mr. Dilip Raj Singhvi | Independent Director |
| Ms. Shilpa Bung | Independent Woman Director |
FAQ
What is the intrinsic value of Gennex Laboratories Ltd?
Gennex Laboratories Ltd's intrinsic value (as of 01 January 2026) is ₹15.73 which is 6.28% higher the current market price of ₹14.80, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹359 Cr. market cap, FY2025-2026 high/low of ₹19.0/10.8, reserves of ₹189 Cr, and liabilities of ₹357 Cr.
What is the Market Cap of Gennex Laboratories Ltd?
The Market Cap of Gennex Laboratories Ltd is 359 Cr..
What is the current Stock Price of Gennex Laboratories Ltd as on 01 January 2026?
The current stock price of Gennex Laboratories Ltd as on 01 January 2026 is ₹14.8.
What is the High / Low of Gennex Laboratories Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Gennex Laboratories Ltd stocks is ₹19.0/10.8.
What is the Stock P/E of Gennex Laboratories Ltd?
The Stock P/E of Gennex Laboratories Ltd is 21.5.
What is the Book Value of Gennex Laboratories Ltd?
The Book Value of Gennex Laboratories Ltd is 8.79.
What is the Dividend Yield of Gennex Laboratories Ltd?
The Dividend Yield of Gennex Laboratories Ltd is 0.00 %.
What is the ROCE of Gennex Laboratories Ltd?
The ROCE of Gennex Laboratories Ltd is 13.0 %.
What is the ROE of Gennex Laboratories Ltd?
The ROE of Gennex Laboratories Ltd is 10.2 %.
What is the Face Value of Gennex Laboratories Ltd?
The Face Value of Gennex Laboratories Ltd is 1.00.